HomeAI · summaries
Storia in 2 fonti
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs - Sarepta Therapeutics (NASDAQ
FDA accepts Sarepta's filings seeking traditional approval for AMONDYS 45 and VYONDYS 53, with a decision expected by February 2027.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
benzinga.com
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs - Sarepta Therapeutics (NASDAQ
FDA accepts Sarepta's filings seeking traditional approval for AMONDYS 45 and VYONDYS 53, with a decision expected by February 2027.
- ·
fiercepharma.com
Regulatory tracker: FDA sets decision date for Sarepta's DMD drugs
Welcome to Fierce Pharma's regulatory tracker for the second half of 2026. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including…